AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02912260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02209142 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: blood prelevement
Description: blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
Study NCT02209142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood prelevement
Description: blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
Study NCT02209142 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: psychometric data collection
Study NCT02209142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychometric data collection
Study NCT02180984 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
Study NCT02180984 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
Study NCT02636751 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Walking aid adjustment
Description: Walking aid adjustment
Study NCT01070095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Asthma Action Plan System
Description: The electronic asthma action plan system consists of a tablet device in the physician waiting room which participants use to complete a simple questionnaire, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and finally, a printable asthma action plan that is given to patients, along with the URL for an asthma education website.
Study NCT02350686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
Study NCT02350686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
Study NCT03781258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: Anti-thrombotic monotherapy (ASA)-Warfarin withdrawal.
Study NCT02647970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUFA-Cys/Met diet
Description: Provision of food and supplements that are rich in polyunsaturated fatty acids (PUFA, n-3 and n-6) and low in the amino acids cysteine (Cys) and methionine (Met).
Study NCT02647970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SFA+Cys/Met diet
Description: Provision of food and supplements that are rich in saturated fatty acids (SFA) and the amino acids cysteine (Cys) and methionine (Met).
Study NCT00927511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
Study NCT00927511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
Study NCT02212990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Arm
Description: Blinded Therapy
Study NCT02636751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information about pain control
Description: General information about pain control, such as ice application and medication usage
Study NCT02636751 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information about pain control
Description: General information about pain control, such as ice application and medication usage
Study NCT02212990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Blinded Therapy
Study NCT02212990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Arm
Description: Open Label Therapy
Study NCT02339350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose methotrexate
Description: HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
Study NCT02339350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal triple chemotherapy
Description: Intrathecal triple chemotherapy for SEG group instead of radiotherapy
Study NCT02824601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: 1-visit-treatment (n=12): Chemomechanical preparation (CMP) - CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP
Study NCT02824601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Description: 2-visit-treatment (n=12): Chemomechanical preparation (CMP) + Ca(OH)2 + SSL medication for 14-days + PDT. CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after 14-days of intracanal medication
Study NCT01878084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bioactive glass (sol-gel)
Description: Extraction sockets will be augmented using bioactive glass (sol-gel)
Study NCT01878084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: empty extraction socket
Description: Extraction socket will be left empty
Study NCT02232828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective removal
Description: Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
Study NCT02232828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepwise removal
Description: Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.~If allocated to stepwise excavation, the second excavation will now be performed as described until only hard, dry dentin remains. Restoration will again be provided adhesively as described.
Study NCT02877095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: subcutaneous furosemide delivered via subcutaneous pump
Study NCT00003779 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Connaught
Description: Compare two strains of BCG
Study NCT00003779 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tice
Description: Compare two strains of BCG
Study NCT04282317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI scan
Description: MRI scan
Study NCT01293019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: Real treatment of osteopathy
Study NCT00831545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
Study NCT01293019 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Placebo
Description: Sham treatment of osteopathy
Study NCT01293019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Classical treatment of pain in cystic fibrosis patients
Study NCT01556815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Description: Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
Study NCT01556815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sorafenib in combination with TACE
Description: Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.~Procedure: TACE~TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
Study NCT04561882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter exclusion of atrial septal aneurysm
Description: Through transseptal perforation, transcatheter reconstruction of atrial septum was achieved with PFO occluder to cover the whole ASA.~Device: Cardi-O-Fix™ patent foramen ovale occluder (Starway Medical Technology, Inc. Beijing, CN)
Study NCT02960763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Augmentation
Description: Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
Study NCT02960763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Augmentation
Description: Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
Study NCT02960763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to bupropion
Description: Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
Study NCT02960763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Augmentation
Description: Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
Study NCT02960763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to nortriptyline
Description: Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
Study NCT02085538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib
Description: palbociclib 125 mg oral capsule with food once
Study NCT02538289 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teaching talks
Description: Two teaching talks specifically addressed to medical staff which concerns the adequate treatment and needs of dyspneic patients, including pharmacological and non-pharmacological treatment.
Study NCT03683693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin group
Description: The ICU physician gets on regular base (day 0, d4, d7, d11, d15, d19, d23, d27) a PCT value and the according non-binding recommendation:~PCT \< 0.5 microgram/L of 80% drop of the peak value : antibiotic stop recommended.~PCT \< 0.25 microgram/L: antibiotic stop strongly recommended. The recommendation is not-binding and can be overruled by the ICU physician. The intervention is only set up for stopping antibiotics, not for initiating. PCT measurements only happens in case of still ongoing antibiotic course. In case of a second course of antibiotics, after interruption of the initial course, new PCT measurement will take place at this point followed by the continuation of the initial schedule of PCT measurement.~Intervention ends 28 days after inclusion.
Study NCT03397329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG-348 Sequence A
Description: 1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)
Study NCT03397329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG-348 Sequence B
Description: 1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)
Study NCT01820572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Study NCT01820572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT01820572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Study NCT04423770 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention; this is a purely observational study
Study NCT02002312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DOTA-girentuximab
Description: Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.~Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments.
Study NCT04324346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC75 (or EC90) x 6
Description: Type of Chemotherapy
Study NCT04324346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC100 + Taxotere (EC90 + Taxotere) 3+3
Description: Type of Chemotherapy
Study NCT04324346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Type of Chemotherapy
Study NCT01144676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine
Description: 25mg dapivirine per ring.~The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
Study NCT01144676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
Study NCT01144676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine
Description: 25mg dapivirine per ring.~The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
Study NCT01144676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
Study NCT01098656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.~Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)
Study NCT01450826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: On day 1, eligible patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide).
Study NCT01450826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.
Study NCT01354665 — intervention group
Intervention type: BIOLOGICAL
Intervention: Interferon beta-1b (Betaferon, BAY86-5046)
Description: Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
Study NCT04634240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Description: PCI of all qualifying lesions.
Study NCT03992170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a human monoclonal antibody (mAb) IgG1 that binds to the highly expressed CD38 protein on the surface of multiple myeloma cells and, at various levels, also in other types of cells and tissues. The CD38 protein has multiple functions, such as receptor-mediated adhesion, signal transduction activity and enzymatic activity.
Study NCT02630329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vNOTES adnexectomy
Description: Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
Study NCT02630329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adnexectomy
Description: Surgical removal of one or both adnexa by transabdominal laparoscopy
Study NCT01620775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRIs
Description: Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.
Study NCT01620775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIs
Description: Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.
Study NCT01620775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain testing
Description: There will be a 1-1.5 hour session including pain tolerance testing.
Study NCT01620775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain testing
Description: There will be a 1-1.5 hour session including pain tolerance testing.
Study NCT01740076 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: soy nuts
Study NCT01740076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soy nuts
Study NCT00852215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus stent
Description: Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
Study NCT00852215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vision stent
Description: Stenting with VISION coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
Study NCT04058535 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eylea
Description: Aflibercept
Study NCT04058535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-L9
Description: Aflibercept biosimilar
Study NCT02680834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Action Pneumatic Compression Device
Description: Dual action pneumatic compression device used to treat chronic VLUs.
Study NCT02680834 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Layer Bandaging
Description: Multi-layer bandaging used to treated chronic VLUs
Study NCT04033341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Administered orally
Study NCT04033341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3214996
Description: Administered orally